Neuromyelitis optica (NMOSD): open trials in China

30 open trials have a site in China. Registry data; only the trial team decides who can take part.

NCT05966467
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
Research · Alexion Pharmaceuticals, Inc.
Beijing · Guangzhou · Henan · Shanghai · Sichuan · Wuhan
Registry updated 2026-10-13
NCT05199688
A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
Trial Treatment · Phase 3 · Hoffmann-La Roche
Guangzhou Women and Children's medical center, Guangzhou · Children's Hospital Of Fudan University, Shanghai
Registry updated 2026-10-01
NCT06620809
The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders
Trial Treatment · Phase 1 · Tongji Hospital
Tongji Hospital, Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan
Registry updated 2026-09-21
NCT06829524
HANDLE-a Real World Study on Satralizumab in NMOSD
Research · Huashan Hospital
Huashan Hospital, Shanghai
Registry updated 2026-09-18
NCT07557420
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Trial Treatment · Phase 3 · Alexion Pharmaceuticals, Inc.
Beijing · Chengdu · Dongguan · Jinan · Shanghai · Shijiazhuang · Taiyuan · Wenzhou · Wuhan
Registry updated 2026-09-11
NCT07809724
Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder
Trial Treatment · Phase 2 · Peking University People's Hospital
Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing
Registry updated 2026-09-09
NCT07762872
A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSD
Research · Junwei Hao, MD
Xuanwu Hospital, Capital Medical University, Beijing
Registry updated 2026-08-13
NCT06502015
Biomarkers in Autoimmune Disease of Nervous System
Research · Tongji Hospital
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Registry updated 2026-07-29
NCT07699770
Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
Trial Treatment · Phase 4 · Tang-Du Hospital
The First Hospital of Tsinghua University, Beijing · Beijing Tiantan Hospital,Capital Medical University, Beijing · The First Hospital of Jilin University, Changchun · The First Affiliated Hospital of Chongqing Medical University, Chongqing · The First Affiliated Hospital of Harbin Medical University, Harbin · Inner Mongolia People's Hospital, Hohhot · The First Affiliated Hospital of Kunming Medical University, Kunming · The First Hospital of China Medical University, Shenyang · Xinjiang Uygur Autonomous Region People's Hospital, Ürümqi · Tangdu Hospotal, Xi'an
Registry updated 2026-07-13
NCT07676266
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Trial Treatment · Phase 1 · The Affiliated Hospital of Qingdao University
The Affiliated Hospital of Qingdao University, Qingdao
Registry updated 2026-06-30
NCT07653984
Cohort Study on Neuroimmune Diseases in the Reproductive Age
Research · Third Affiliated Hospital, Sun Yat-Sen University
The Third Affiliated Hospital,Sun Yat-Sen University, Guangzhou
Registry updated 2026-06-17
NCT07592754
The Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder.
Trial Treatment · Early phase 1 · Chinese PLA General Hospital
Chinese PLA General Hospital, Beijing
Registry updated 2026-05-18
NCT07420296
Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
Trial Treatment · Phase 3 · Tianjin Medical University General Hospital
Tianjin Medical University General Hospital, Department of Neurology, Tianjin
Registry updated 2026-05-14
NCT07526493
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Trial Treatment · Phase 1 · Tongji Hospital
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Registry updated 2026-05-12
NCT06413654
A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
Trial Treatment · Phase 2/3 · Shanghai Jiaolian Drug Research and Development Co., Ltd
Beijing Anzhen Hospital, Capital Medical University, Beijing · The first medical center of PLA general hospital, Beijing · Peking University First Hospital, Beijing · Beijing Tongren Hospital, Capital Medical University, Beijing · Beijing Tiantan Hospital,Capital Medical University, Beijing · The Third Medical Center of PLA General Hospital, Beijing · Cangzhou Central Hospital, Cangzhou · Xiangya Hospital Central South University, Changsha · The Second Xiangya Hospital of Central South University, Changsha · Sichuan Provincial People's Hospital, Chengdu · The First Affiliated Hospital of Fujian Medical University, Fuzhou · Zhujiang Hospital of Southern Medical University, Guangzhou · The Third Affiliated Hospital,Sun Yat-Sen University, Guangzhou · Guangzhou First People's Hospital, Guangzhou · The First Affiliated Hospital, Sun Yat-sen University, Guangzhou · Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou · The Affiliated Hospital of Guizhou Medical University, Guiyang · The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou · The Fourth Affiliated Hospital of Harbin Medical University, Harbin · The Second Affiliated Hospital of Harbin Medical University, Harbin · The Second Affiliated Hospital Of Anhui Medical University, Hefei · Anhui Provincial Hospital, Hefei · Huizhou First Hospital, Huizhou · The First Affiliated Hospital of Shandong First Medical University, Jinan · Affiliated Hospital of Jining Medical University, Jining · First People's Hospital of Yunnan Province, Kunming · First Affiliated Hospital of Kunming Medical University, Kunming · Jiangxi Provincial People's Hospital, Nanchang · Nanyang Central Hospital, Nanyang · Qilu Hospital of Shandong University (Qingdao), Qingdao · The First Hospital of China Medical University, Shenyang · Shenzhen Hospital of University of Hong Kong, Shenzhen · The Second Hospital of Hebei Medical University, Shijiazhuang · Taihe Hospital, Shiyan · Shanxi Provincial People's Hospital, Taiyuan · First Hospital of Shanxi Medical University, Taiyuan · Tianjin Medical University General Hospital, Tianjin · The First Affiliated Hospital of Wenzhou Medical University, Wenzhou · Renmin Hospital of Wuhan University, Wuhan · Tongji Hospital, Wuhan · Zhongshan Hospital Xiamen University, Xiamen · The First Affiliated hospital of Xiamen University, Xiamen · Xi'an International Medical Center Hospital, Xi'an · The Second Affiliated Hospital of the Chinese People's Liberation Army Air Force Medical University, Xi'an · Yan'an University Xianyang Hospital, Xianyang · Yantai Mountain Hospital in Yantai City, Yantai · The Central Hospital of Yongzhou, Yongzhou · Zaozhuang Municipal Hospital, Zaozhuang · Henan Provincial People's Hospital, Zhengzhou · The First Affiliated Hospital of Zhengzhou University, Zhengzhou · Zigong First People's Hospital, Zigong
Registry updated 2026-05-05
NCT07410039
Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study
Trial Treatment · Phase 4 · Chinese PLA General Hospital
The First Medical Center of Chinese PLA General Hospital, Beijing
Registry updated 2026-03-12
NCT07392528
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases
Trial Treatment · Early phase 1 · Tianjin Huanhu Hospital
Tianjin Huanhu Hospital, Tianjin
Registry updated 2026-02-11
NCT05504694
Ofatumumab in AQP4-IgG Seropositive NMOSD
Trial Treatment · Phase 1/2 · Tang-Du Hospital
Tangdu Hospital, Xi'an
Registry updated 2026-01-30
NCT07377305
Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)
Trial Treatment · Tang-Du Hospital
Tangdu Hospital, Xi'an
Registry updated 2026-01-29
NCT06643858
Normal Chinese Lifespan Brain Charts Initiative (NCLBCI)
Research · Beijing Tiantan Hospital
This trial only enrols healthy participants
Beijing Tiantan Hospital,Capital Medical University, Beijing
Registry updated 2025-12-30
NCT07266051
Prospective Cohort Study of Neuromyelitis Optica Spectrum Disorders (NMOSD)
Research · Xiamen Hospital of Traditional Chinese Medicine
Xiamen Hospital of Traditional Chinese Medicine, Xiamen · The Second Affiliated Hospital of Xiamen Medical College, Xiamen · The First Affiliated hospital of Xiamen University, Xiamen · Zhongshan Hospital Xiamen, Fudan University, Xiamen · Zhongshan Hospital Xiamen University, Xiamen
Registry updated 2025-12-18
NCT06939166
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases
Trial Treatment · Early phase 1 · Tianjin Huanhu Hospital
Tianjin Huanhu Hospital, Tianjin
Registry updated 2025-12-15
NCT06885957
Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD
Research · Tongji Hospital
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Registry updated 2025-09-08
NCT06249438
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Trial Treatment · Phase 1 · RenJi Hospital
Department of Rheumatology, RenJi Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai
Registry updated 2025-07-25
NCT06763848
Protein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder
Trial Treatment · Third Affiliated Hospital, Sun Yat-Sen University
The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou
Registry updated 2025-04-30

All Neuromyelitis optica (NMOSD) trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error